Capstone has announced that its human insulin biosimilar received positive opinions from the European Medicines Agency and Health Canada, signaling approvals may be on the horizon, and the acquisition of Viatris’ biosimilars portfolio by Biocon Biologics is officially complete.
Capstone has announced that its human insulin biosimilar received positive opinions from the European Medicines Agency and Health Canada, signaling approvals may be on the horizon, and the acquisition of Viatris’ biosimilars portfolio by Biocon Biologics is officially complete.
European and Canadian Insulin Progress
Capstone Development Services Company shared that its biosimilar human insulin received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, sending it on to the European Commission for final review before approval. Additionally, the same biosimilar received a Notice of Compliance from Health Canada, meaning that the product has been approved for use.
The biosimilar was developed by Capstone’s affiliate company, Celerity Pharmaceuticals, and is formulated as an intravenous infusion in a flexible plastic container in 0.9% sodium chloride injection. If approved, the biosimilar could be administered to patients in hospitals and other acute settings.
The European and Canadian filings represent the 17th and 18th regulatory processes that Capstone has participated in for products developed in partnership with global pharmaceutical and medical organizations since 2013, when Capstone was founded.
“We are honored to be part of successfully developing this innovative presentation of insulin to advance our partner's goal of introducing medicines that help promote efficiency for clinicians and provide patients with a better experience,” said Dan Robins, PhD, president of Capstone.
Biocon Biologics Acquisition of Viatris’ Biosimilars Completed
Viatris announced that its transaction with Biocon Biologics Limited is closed, officially completing the transition of Viatris’ entire biosimilars portfolio to Biocon Biologics.
The companies entered a Transition Services Agreement in March 2022, during which Viatris will provide commercialization assistance and transition services for a 2-year period to ensure business continuity for patients and other stakeholders. Biocon Biologics will be responsible for commercial, regulatory, and other related services.
“The closing of our biosimilars transaction with Biocon Biologics marks the next natural step in the evolution of our collaboration together… As we look to Viatris' future, we are also excited to focus our energy, resources, and efforts on executing our own strategy of moving up the value chain and providing access to more complex and novel products,” commented Rajiv Malik, MPharm, president of Viatris.
As part of the agreement, Viatris received $3 billion in consideration, including at least a 12.9% stake valued at $1 billion in Biocon Biologics. Viatris will also receive an additional cash payment of $335 million in 2024.
In 2022, Viatris and Biocon Biologics launched Abevmy, a bevacizumab biosimilar referencing Avastin, in Canada for the treatment of several forms of cancer. Viatris, which resulted from the completion of a merger between Mylan Pharmaceuticals and Upjoin, also had to recall particular batches of its unbranded insulin glargine biosimilar twice this year.
Viatris and its partner Momenta Pharmaceuticals shared positive results from the phase 3 INSIGHT study evaluating the safety and efficacy of an aflibercept biosimilar candidate (MYL-1701P) referencing Eylea at the American Academy of Ophthalmology’s annual conference.
In November 2022, Biocon, Biocon Biologic’s parent company, shared its quarterly revenues report, revealing that Biocon Biologics’ revenue from biosimilars was up 34% year over year. The company also licensed out 2 of its biosimilars, an ustekinumab and a denosumab, to Yoshindo for the Japanese market.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.